S. 1375 118th Congress
HELP Copays Act
Latest action, Apr 27, 2023: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
25 cosponsors
Sponsored by Roger Marshall (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
16 D · 8 R · 1 I
- Democrat
- Republican
- Independent
Referred to: Senate: Health, Education, Labor, and Pensions Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
8 reports
7 reports
ABBVIE, INC.
FEDERAL STREET STRATEGIES, LLC
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
All 25 of 58 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| INFUSION PROVIDERS ALLIANCE | 8 | $216K | Q1 2023 | Q3 2024 | yes | |
| ABBVIE INC. | 7 | $6.7M | Q4 2023 | Q3 2024 | yes | |
| ABBVIE, INC. | FEDERAL STREET STRATEGIES, LLC | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | 7 | $5.0M | Q4 2023 | Q3 2024 | yes | |
| AMERICAN COLLEGE OF RHEUMATOLOGY | 7 | $670K | Q4 2023 | Q3 2024 | yes | |
| AMERICAN MEDICAL ASSOCIATION | 7 | $38.2M | Q4 2023 | Q3 2024 | yes | |
| AMGEN INC | 7 | $20.1M | Q4 2023 | Q3 2024 | yes | |
| ASSOCIATION FOR CLINICAL ONCOLOGY | 7 | $1.6M | Q4 2023 | Q3 2024 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 7 | $13.3M | Q4 2023 | Q3 2024 | yes | |
| CYSTIC FIBROSIS FOUNDATION | 7 | $1.4M | Q4 2023 | Q3 2024 | yes | |
| EMD SERONO INC | 7 | $4.7M | Q4 2023 | Q3 2024 | yes | |
| EPILEPSY FOUNDATION | 7 | $430K | Q4 2023 | Q3 2024 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.2M | Q4 2023 | Q3 2024 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 7 | $12.1M | Q4 2023 | Q3 2024 | yes | |
| LUNDBECK LLC | 7 | $910K | Q4 2023 | Q3 2024 | yes | |
| NOVARTIS | 7 | $9.2M | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $50.1M | Q4 2023 | Q3 2024 | yes | |
| SANOFI US SERVICES INC | 7 | $9.0M | Q4 2023 | Q3 2024 | yes | |
| SUSAN G. KOMEN | ARTEMIS POLICY GROUP LLC | 7 | $280K | Q4 2023 | Q3 2024 | yes |
| TAKEDA PHARMACEUTICALS AMERICA INC | 7 | $6.0M | Q4 2023 | Q3 2024 | yes | |
| THE ALS ASSOCIATION | 7 | $185K | Q4 2023 | Q3 2024 | yes | |
| THE HEMOPHILIA ALLIANCE | ARTEMIS POLICY GROUP LLC | 7 | $280K | Q4 2023 | Q3 2024 | yes |
| THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 7 | $510K | Q4 2023 | Q3 2024 | yes | |
| THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | 7 | $540K | Q4 2023 | Q3 2024 | yes | |
| TRAVERE THERAPEUTICS | ALSTON & BIRD LLP | 7 | $0 | Q4 2023 | Q3 2024 | yes |